Sacubitril and Valsartan established it and there were a lot of other studies that added to its flavour with the last one, TRANSITION, a few months back. And, now, it is the turn of the new brand, validating something that was almost a no-brainer, just as what TRANSITION did. Sacubitril-Valsartan (LCZ-696) is the latest advancement over ALL other therapies including ACE-I/ARB even though some old-school cardiologists prefer to deny that status to LCZ-696. Nevertheless, their opinion notwithstanding, there has never ever been such an improvement in all hard end-points with any therapy OVER the background of existing care of therapy.
And, with the additional carrot of better tolerability and greater safety. Having said that, let us not get over-awed by all these acronyms and much-hyped RCTs and keep our feet firmly planted on the ground. LCZ-696, like any established therapy, has to be…
